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OBJECTIVE — To determine whether the association observed between poor glycemic con-
trol and low HDL cholesterol in type 2 diabetes is dependent on obesity and/or
hypertriglyceridemia.
RESEARCH DESIGN AND METHODS — We performed a cross-sectional study of
1,819 patients with type 2 diabetes and triglycerides 400 mg/dl enrolled at three diabetes
centers in Italy. The risk for low HDL cholesterol was analyzed as a function of A1C levels. Odds
ratios (ORs) were calculated after adjustment for confounding factors.
RESULTS — A 1% increase in A1C signiﬁcantly increased the risk for low HDL cholesterol
(OR 1.17 [95% CI 1.1–1.2], P  0.00072); no changes were observed when age, sex, smoking,
and lipid-lowering therapy were included in the model (1.17 [1.1–1.2], P  0.00044). The
association remained strong after adjustments for obesity and hypertriglyceridemia in multivar-
iate analysis (1.12 [1.05–1.18], P  0.00017).
CONCLUSIONS — Poor glycemic control appears to be an independent risk factor for low
HDL cholesterol in type 2 diabetes.
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C
ardiovasculardisease(CVD)isama-
jor cause of morbidity and mortality
in patients with type 2 diabetes
(1,2). Several studies have shown that ag-
gressive comprehensive management of
the mixed dyslipidemia associated with
the metabolic syndrome and type 2 dia-
betes is needed to reduce the increased
cardiovascular risk (3,4). Despite this ev-
idence, treatments do not completely ad-
dress all the components of diabetic
dyslipidemia and therapeutic targets are
stillnotachieved(5).Nearlyhalfoftype2
diabetic patients have low levels of HDL
cholesterol (5), a key component of dia-
betes-related dyslipidemia and a strong
independent risk factor for CVD. HDL
cholesterol is inversely correlated with
cardiovascular risk, even when LDL cho-
lesterolhasbeenreducedwithstatinther-
apy (6–7).
An inverse relationship between HDL
cholesterol and A1C levels has been de-
scribedintype2diabeticpatients(8,9).It
is unclear, however, whether this rela-
tionship is partly dependent on obesity
and/or hypertriglyceridemia, which are
known determinants of low HDL choles-
terol and frequently found in patients
with poorly controlled diabetes. This
study was designed to test the hypothesis
thatglycemiccontrolisindependentlyas-
sociated with HDL cholesterol in patients
with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— A cross-sectional study
of 1,819 consecutive patients with type 2
diabetes and serum triglycerides 400
mg/dl was conducted at diabetes centers
in three Italian cities (San Giovanni Ro-
tondo [SGR], Catanzaro [CZ], and Rome)
with institutional review board approval.
Age, sex, height and weight, medical his-
tory, smoking status (current smokers vs.
nonsmokers), and current medications—
lipid-lowering agents in particular—were
recorded for all patients. Venous blood
sampleswerecollectedafterafastof8h
andanalyzedtodetermineserumlevelsof
A1C (high-performance liquid chroma-
tography, normal range 3–6%), glucose
(glucose-oxidase method), cholesterol
(totalandHDL),andtriglycerides(standard
enzymatic assays). LDL cholesterol was cal-
culated with the Friedewald formula: LDL
cholesteroltotalcholesterol(HDLcho-
lesterol[triglycerides/5]).LowHDLcho-
lesterol was deﬁned as levels of 40
mg/dl(men)or50mg/dl(women)(10).
Statistical analysis
Data are reported as means  SD. Mean
differences were compared by unpaired
Students’ t tests. Variables displaying
skewed distribution (i.e., triglycerides)
were logarithmically transformed. Multi-
variate logistic regression analysis was
used to assess the effect of metabolic con-
trol on the presence/absence of low HDL
cholesterol. Results were expressed as
odds ratio (OR) and 95% CI. After exclu-
sion of intersample heterogeneity, the
three data sets were pooled and analyzed
together following adjustments for sam-
ple. Analyses were performed with SPSS
software, version 15 (SPSS, Chicago, IL),
and a P value of 0.05 was considered
signiﬁcant.
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clinicalandbiochemicalcharacteristicsof
the three populations studied. Higher
A1C levels were recorded in SGR and CZ
(P  0.001 vs. Rome). The prevalence of
low HDL cholesterol ranged from 28% in
Rome to 34% in CZ and 55% in SGR. In
SGR, patients were more frequently
treated with insulin than with oral hypo-
glycemic agents compared with the pa-
tients in Rome and CZ; moreover, a
smaller percentage of patients in SGR and
CZ were treated with hypolipemic ther-
apy than in Rome. At all three centers,
A1C levels tended to be higher in patients
with low HDL cholesterol than in those
with HDL cholesterol levels 40/50 mg/
dl. This difference was statistically signif-
icant in SGR (8.7 vs. 8.3%, P  0.0001)
and Rome (7.0 vs. 6.7%, P  0.04) but
not in CZ (7.8 vs. 7.5%, P  0.2). There
wasnosigniﬁcantinteractionbetweenthe
variables A1C level and sample in modu-
lation of the risk of low HDL cholesterol
(P  0.86).
Analysisofpooleddatarevealedthata
1% increase in A1C values signiﬁcantly
increasedtheriskforlowHDLcholesterol
(OR 1.17 [95% CI 1.1–1.2], P 
0.00072). This effect did not change at all
when age, sex, smoking status, and lipid-
lowering therapy were added to the
model (1.17 [1.1–1.2], P  0.00044).
The strength of this association was also
maintained when additional adjustments
for obesity (BMI 30 kg/m
2) and hyper-
triglyceridemia (150 mg/dl) were in-
cluded in the multivariate analysis 1.12
[1.05–1.18], P  0.00017).
The linear regression from individual
data between A1C and HDL cholesterol is
shown in the online appendix available at
http://care.diabetesjournals.org/cgi/content/
full/dc09-0256/DC1.
CONCLUSIONS— LDL cholesterol
lowering therapy with statins reduces
CVD in patients with type 2 diabetes and
is recommended by current guidelines as
theﬁrst-lineapproachforthetreatmentof
diabetic dyslipidemia (11). However, pa-
tients who achieve LDL cholesterol tar-
gets with statins may have a “residual”
elevation of cardiovascular risk related to
low HDL cholesterol, which is an inde-
pendent predictor of major cardiovascu-
lar events (12). Consequently, increasing
HDL cholesterol levels is now being pro-
posed as an additional worthwhile thera-
peutic goal in diabetes (11). Because
nearly half of all type 2 diabetic patients
have low HDL cholesterol levels (5), the
variables associated with this phenome-
non need to be clearly deﬁned.
In the large Italian diabetic popula-
tion we studied, low HDL cholesterol was
strongly associated with higher A1C lev-
els. This observation is consistent with
previousreports(5,8,9,13).Lopes-Virella
et al. (13) demonstrated a negative corre-
lation between HDL cholesterol and se-
rum glucose levels in diabetic subjects.
Moreinteresting,ourstudyfoundthe
association between poor glycemic con-
trol and low HDL cholesterol remained
signiﬁcantevenafteradjustmentsforobe-
sity and hypertriglyceridemia. Both are
highly prevalent in patients with type 2
diabetes, especially in those with poor
glycemic control, and are known to inde-
pendently lower HDL cholesterol. Exper-
imental ﬁndings demonstrated that
glycation of HDL cholesterol impairs its
functional ability to bind to the receptor
and to promote intracellular cholesterol
efﬂux (14).
It has also been observed that poor
glycemic control promotes glycation of
the protein component of HDL choles-
terol (apolipoprotein A1), altering HDL
cholesterol metabolism and its ability to
activate lecithin-cholesterol acyltrans-
ferase and the reverse cholesterol trans-
port pathway (15). This is a mechanism
by which glycated HDL cholesterol could
worsen diabetic atherosclerosis.
To our knowledge, these ﬁndings are
the ﬁrst evidence that impaired glycemic
control is an important independent risk
factor for low HDL cholesterol in patients
with type 2 diabetes. If conﬁrmed in fu-
turestudies,thisobservationmayprovide
an additional means for establishing opti-
malglycemictargetstailoredtoindividual
patient characteristics.
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